MedTrace Logo

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

NCT05836948 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2025-08-11

No results posted yet for this study

Summary

This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SHR-9839

Weekly fixed dose injection of SHR-9839

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-18
Primary Completion
2026-05-01
Completion
2026-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05836948 on ClinicalTrials.gov